Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year updateThomas H. Brannagan, John L. Berk, Brian Drachman et al.|Journal of Neurology|2022Cited by 36
ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtableThomas H. Brannagan, Frederick L. Ruberg, Michaela Auer‐Grumbach et al.|Orphanet Journal of Rare Diseases|2021Cited by 16
Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosisTeresa Coelho, Morie A. Gertz, Carol Whelan et al.|Journal of the Neurological Sciences|2021Cited by 0